Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 5Observational 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Amplified Fragment Length Polymorphism Analysis 4Bevacizumab 3Radiomics 2Paclitaxel 2Observation 2Gene Expression Profiling 2Carboplatin 2capmatinib 1Watchful Waiting 1Tomography, X-Ray Computed 1Polymerase Chain Reaction 1Microarray Analysis 1Mastectomy, Segmental 1Immunohistochemistry 1High-Throughput Nucleotide Sequencing 1Exome 1Diagnostic Imaging 1DNA Methylation 1DNA Copy Number Variations 1Chromosome Mapping 1Biopsy 1Biomarkers 1Base Sequence 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Adenocarcinoma of Lung × capmatinib × Clear all
NCT05703516 2026-06-01

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Novartis

Recruiting
44 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡